Vor Biopharma Inc. (VOR): Total Assets
$464.13M
As of 2025-12-31
$481.05M
As of 2026-06-30
+15.7%
3-year compound annual growth
+43.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $464.13M | +224.8% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $142.89M | -27.9% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $198.13M | -33.8% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $299.37M | +23.4% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $242.59M | +219.6% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $75.91M | n/a | 2022-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $464.13M | +224.8% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $453.03M | -2.8% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $448.66M | +2.3% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $448.37M | -27.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $487.97M | +12.8% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $501.90M | +31.1% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $512.74M | -4.9% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $514.16M | +4.8% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $416.89M | -16.8% |
Compare VOR, RGNX, GLUE, CGEM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗